Serina King

A phase I study of muscadine grape skin extract in men with biochemically recurrent prostate cancer: Safety, tolerability, and dose determination

G. Rosner, Xiaoping Zhou, C. Drake, 2015, The Prostate.

Combination of the histone deacetylase inhibitor vorinostat with bevacizumab in patients with clear-cell renal cell carcinoma: a multicentre, single-arm phase I/II clinical trial

R. Wahl, S. Rehman, M. Lodge, 2017, British Journal of Cancer.

Phase I study of MGCD0103 given as a three-times-per-week oral dose in patients with advanced solid tumors.

M. Carducci, L. Siu, A. Kalita, 2008, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Repurposing itraconazole as a treatment for advanced prostate cancer: a noncomparative randomized phase II trial in men with metastatic castration-resistant prostate cancer.

Ming Zhao, David C. Smith, Janet Mendonca, 2013, The oncologist.

Randomized Phase II Trial of Sipuleucel-T with or without Radium-223 in Men with Bone-metastatic Castration-resistant Prostate Cancer

D. Song, C. Drake, P. Tran, 2021, Clinical Cancer Research.

TRIUMPH: Phase II trial of rucaparib monotherapy in patients with metastatic hormone-sensitive prostate cancer harboring germline DNA repair gene mutations.

Hao Wang, E. Antonarakis, C. Sternberg, 2023, Journal of Clinical Oncology.

A phase I study of OSI-461 in combination with mitoxantrone in patients with advanced solid tumors potentially responsive to mitoxantrone

M. Carducci, M. Eisenberger, C. Sweeney, 2010, Cancer Chemotherapy and Pharmacology.

Olaparib Without Androgen Deprivation for High-Risk Biochemically Recurrent Prostate Cancer Following Prostatectomy: A Nonrandomized Controlled Trial.

E. Davicioni, M. Carducci, M. Eisenberger, 2024, JAMA oncology.

Muscadine Grape Skin Extract (MPX) in Men with Biochemically Recurrent Prostate Cancer: A Randomized, Multicenter, Placebo-Controlled Clinical Trial

G. Rosner, C. Drake, E. Antonarakis, 2017, Clinical Cancer Research.